Patents Examined by Barbara P. Badio
  • Patent number: 12005033
    Abstract: The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: June 11, 2024
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
  • Patent number: 12005066
    Abstract: Methods and compositions for treating cyanide, sulfide, or methane-thiol exposure in a subject. The compositions may include one or more cobinamide compounds, such as an amino-tetrazole-cobinamide and/or a di-(amino-tetrazole)-cobinamide.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: June 11, 2024
    Assignees: The Regents of the University of California, The Regents of the University of Colorado
    Inventors: Gerard Boss, Adriano Chan, Matthew Brenner, Sari Brenner Mahon, Vikhyat Bebarta
  • Patent number: 11998540
    Abstract: The present invention provides compositions and methods for the treatment of drug-tolerant glioblastoma, and in particular glioblastoma stem cells. Specifically, the methods comprise contacting a glioblastoma stem cell with a platelet-derived growth factor receptor alpha inhibitor and one or more of a histone lysine demethylase inhibitor and a Notch inhibitor.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: June 4, 2024
    Assignee: The General Hospital Corporation
    Inventors: Brian B. Liau, Anoop P. Patel, Cem Sievers, Bradley E. Bernstein
  • Patent number: 11999765
    Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(O)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Grant
    Filed: June 13, 2023
    Date of Patent: June 4, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Maria Jesus Blanco-Pillado, Francesco G. Salituro, Marshall Lee Morningstar
  • Patent number: 11987559
    Abstract: A 1-(4-bromobenzylideneamino)-5-phenylimidazolidine-2,4-dione compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 31, 2023
    Date of Patent: May 21, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11980602
    Abstract: A prodrug compound of cannabidiol (CBD), pharmaceutical composition thereof and methods of use thereof in patients in need.
    Type: Grant
    Filed: March 24, 2022
    Date of Patent: May 14, 2024
    Assignee: Firstlight Pharmaceuticals LLC
    Inventor: Kieran John
  • Patent number: 11970458
    Abstract: An 4,5-bis(4-bromophenyl)-1-hexyl-2-(4-nitrophenyl)-1H-imidazole compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 27, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
  • Patent number: 11970514
    Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(0)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Grant
    Filed: June 13, 2023
    Date of Patent: April 30, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Maria Jesus Blanco-Pillado, Francesco G. Salituro, Marshall Lee Morningstar
  • Patent number: 11963941
    Abstract: A compound having antiestrogenic activity is used in a method for the treatment of BC or other estrogen-responsive tumors in a human patient, wherein the method comprises subjecting the patient to a fasting mimicking diet for a period of 24-190 hours while the patient is being treated with the compound having antiestrogenic activity, which can be a selective estrogen receptor modulator (SERM), a selective estrogen receptor downregulator (SERD) or an aromatase inhibitor (AI).
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: April 23, 2024
    Assignees: UNIVERSITA' DEGLI STUDI DI, L-NUTRA INC.
    Inventors: Alessio Nencioni, Alberto Ballestrero, Patrizio Odetti, Fiammetta Monacelli, Irene Caffa, Valter Longo
  • Patent number: 11958811
    Abstract: An 1-[4,5-bis(4-bromophenyl)-1-hexyl-1H-imidazol-2-yl]-2-naphthol compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 27, 2023
    Date of Patent: April 16, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
  • Patent number: 11950592
    Abstract: A method for remarkably enhancing plant disease controlling effects, and a method for controlling plant diseases are provided. A method for enhancing plant disease controlling effects of an aryl phenyl ketone fungicide includes using an aryl phenyl ketone fungicide as a component (a) in combination with at least one component (b) selected from the group consisting of a nonionic surfactant, an anionic surfactant, a cationic surfactant, a vegetable oil, a paraffin, a resin and a terpene.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: April 9, 2024
    Assignee: ISHIHARA SANGYO KAISHA, LTD.
    Inventors: Munekazu Ogawa, Akihiro Nishimura, Shuko Nishimi
  • Patent number: 11945836
    Abstract: Described herein are neuroactive steroids of the Formula (II): or a pharmaceutically acceptable salt thereof; wherein A, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6 and are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Grant
    Filed: October 4, 2022
    Date of Patent: April 2, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
  • Patent number: 11938141
    Abstract: The present invention refers to a new enzymatic process for obtaining 17?-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17?,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17?-propionate and 9,11-dehydro-cortexolone 17?-butanoate.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: March 26, 2024
    Assignee: CASSIOPEA S.P.A.
    Inventors: Mauro Ajani, Luigi Moro
  • Patent number: 11939601
    Abstract: This disclosure relates to mRNA therapy for the treatment of hyperphenylalaninemias such as phenylketonuria (PKU). mRNAs for use in the invention, when administered in vivo, encode human phenylalanine hydroxylase (PAH), functional fragments thereof (e.g., those comprising the catalytic domain or the catalytic domain and the tetramerization domains), and fusion proteins comprising PAH. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PAH expression and/or activity in subjects. mRNA therapies of the invention further decrease abnormal accumulation of phenylalanine associated with deficient PAH activity in subjects.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: March 26, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Raj Rajendran, Patrick Finn, Paolo G. V. Martini, Ding An, Athanasios Dousis, Kanchana Ravichandran
  • Patent number: 11919892
    Abstract: A 2-(benzo[d]thiazol-2-yl)-N?-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio) acetoxy)acetimidamide compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 11, 2023
    Date of Patent: March 5, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11912738
    Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(0)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Grant
    Filed: June 13, 2023
    Date of Patent: February 27, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Maria Jesus Blanco-Pillado, Francesco G. Salituro, Marshall Lee Morningstar
  • Patent number: 11905309
    Abstract: 3beta, 17beta disubstituted steroidal compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, are provided for the prevention and treatment of a variety of CNS-related conditions.
    Type: Grant
    Filed: July 21, 2021
    Date of Patent: February 20, 2024
    Assignee: SAGE THERAPEUTICS, INC.
    Inventors: Gabriel Martinez Botella, Boyd L Harrison, Albert Jean Robichaud, Francesco G. Salituro
  • Patent number: 11884696
    Abstract: This invention relates to a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I), and compositions thereof. Also disclosed herein are methods of making the same and methods of using the same.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: January 30, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Paul Steven Watson, Bret Berner, John Gregory Reid, Jian Wang, James J. Doherty, Stephen Jay Kanes
  • Patent number: 11873320
    Abstract: The present invention relates generally to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide, polymorphic forms thereof, methods for preparation and use thereof, pharmaceutical compositions thereof, and kits and articles of manufacture thereof.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: January 16, 2024
    Assignee: REATA PHARMACEUTICALS HOLDINGS, LLC
    Inventors: Ahmad Y. Sheikh, Alessandra Mattei, Xiu C. Wang
  • Patent number: 11857556
    Abstract: The present invention relates to a composition for topical application for preventing hair loss, androgenic alopecia (AA) and stimulating hair growth having dutasteride. The composition for topical application for preventing hair loss and stimulating hair growth according to the present invention provides equal or superior hair loss prevention and hair growth stimulating effects while using much smaller dosage than the conventional compositions (oral dosage form) which use finasteride and dutasteride.
    Type: Grant
    Filed: April 26, 2021
    Date of Patent: January 2, 2024
    Assignee: SHILPA MEDICARE LIMITED
    Inventors: Rajendar Medishetty, Agadihiremath Thippeswamy, Sreenivasa Reddy, Shivakumar Pradeep